Bacterial immunotoxins have been used in clinical trials to successfully treat hematological malignancies and solid tumors, as well as used as an adjuvant therapy targeting mesothelin-expressing mesothelioma, ovarian, or pancreatic cancer [62-66]. Here, MSLN is linked to hematologic disorder.